Stephens & Co. Maintains Overweight on Cytek Biosciences, Raises Price Target to $7
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
Stephens & Co. analyst Mason Carrico maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and raises the price target from $6 to $7.
Stephens & Co. analyst Mason Carrico maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and raises the price target from $6 to $7.